NCT02144389

Arachidonic Acid Treatment Against Schistosomiasis Infection in Children

Effects of Arachidonic Acid Supplementation on Schistosomiasis Mansoni Infection in Egyptian School Children

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 335 (actual)
• Sponsor: dsm-firmenich Switzerland AG · Industry
• Sex: All
• Age: 6 Years – 15 Years
• Healthy volunteers: Not accepted

Summary

Randomized Controlled Trial: The investigational materials used in this trial were administered to subjects each day by trained clinicians. Primary Objectives: * assess the effect of dietary supplementation with arachidonic acid on the cure rates for Schistosomiasis mansoni with and without concomitant treatment with praziquantel. * assess the safety of dietary supplementation using arachidonic acid in children with clinically confirmed schistosomiasis mansoni infection. Secondary objective: * to measure changes in total phospholipids in plasma.

Conditions

• Schistosomiasis
• Bilharzia

Interventions

Type	Name	Description
DRUG	Praziquantel (PZQ)	40 mg/kg, a single dose, administered orally 1 g of corn/soybean oil (50%/50%), administered orally
DIETARY_SUPPLEMENT	Arachidonic acid (ARA)	ARA (40% of total fatty acid)
DIETARY_SUPPLEMENT	PZQ+ARA	A single dose of PZQ administered seven days in advance of initial treatment with ARA.

Timeline

• Start date: 2013-01-01
• Primary completion: 2013-07-01
• Completion: 2014-01-01
• First posted: 2014-05-22
• Last updated: 2014-05-22

Locations

3 sites across 1 country: Egypt